Notícias Lexicon Pharmaceuticals Inc - LXRX | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Lexicon Pharmaceuticals Inc (LXRX)
Lexicon Pharmaceuticals Inc (LXRX) Notícias

Lexicon Pharmaceuticals Inc (LXRX)

0,8634

0,0917

(11,88%)

Fechado 24 Novembro 6:00PM

Atrasado por 15 minutos

0,8601

-0,0033

(-0,38%)

Após o horário de negociação: 9:52PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Form 8-K - Current report

Lexicon Appoints Ivan H. Cheung to Board of Directors

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Form 8-K - Current report

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Lexicon Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições